Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats

International Journal of Neuropsychopharmacology

Volumn 11, Issue 6, 2008, Pages 845-850

  Wiker, Charlotte ^a   Schilström, Björn ^a   Sandbäck, Carina ^a   Wadenberg, Marie Louise ^b   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LINNAEUS UNIVERSITY   (Sweden)

Author keywords

Antipsychotic drugs; Conditioned avoidance response; Donepezil; Galantamine; Schizophrenia

Indexed keywords

ACETYLCHOLINESTERASE; DONEPEZIL; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; GALANTAMINE; NICOTINIC RECEPTOR; RACLOPRIDE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CATALEPSY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CHOLINESTERASE INHIBITORS; CONDITIONING (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FREEZING REACTION, CATALEPTIC; GALANTAMINE; INDANS; MALE; PIPERIDINES; RACLOPRIDE; RATS; RATS, WISTAR;

EID: 50849135219     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708008730     Document Type: Article

References (25)

1. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R (1998). Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia Bulletin 24, 189-202.
2. Allen TB, McEvoy JP (2002). Galantamine for treatment-resistant schizophrenia. American Journal of Psychiatry 159, 1244-1245.
3. Andersen MB, Werge T, Fink-Jensen A (2007). The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in cebus monkeys. Journal of Pharmacology and Experimental Therapeutics 321, 1179-1182.
4. Bymaster FP, Shannon HE, Rasmussen K, Delapp NW, Mitch CH, Ward JS, Calligaro DO, Ludvigsen TS, Sheardown MJ, Olesen PH, et al. (1998). Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane. European Journal of Pharmacology 356, 109-119.
5. Cummings JL, McRae T, Zhang R (2006). Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. American Journal of Geriatric Psychiatry 14, 605-612.
6. Eltayb A, Wadenberg ML, Svensson TH (2005). Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa. Biological Psychiatry 58, 337-343.
7. Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, Light GA (2005). Efficacy and tolerability of low-dose donepezil in schizophrenia. Clinical Neuropharmacology 28, 179-184.
8. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, et al. (1997). Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proceedings of the National Academy of Sciences USA 94, 587-592.
9. Freudenreich O, Herz L, Deckersbach T, Evins AE, Henderson DC, Cather C, Goff DC (2005). Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berlin) 181, 358-363.
10. Geerts H, Guillaumat P-O, Grantham C, Bode W, Anciaux K, Sachak S (2005). Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rat, mice, and rabbits. Brain Research 1033, 186-193.
11. Hertel P, Fagerquist MV, Svensson TH (1999). Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286, 105-107.
12. Hohnadel E, Bouchard K, Terry Jr. AV (2007). Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology 52, 542-551.
13. Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R (2007). Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology. Published online: 11 July 2007. doi:10.1038/sj.npp.1301499.
14. Kuroki T, Meltzer HY, Ichikawa J (1999). Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics 288, 774-781.
15. Lee SW, Lee JG, Lee BJ, Kim YH (2007). A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. International Clinical Psychopharmacology 22, 63-68.
16. Luntz-Leybman V, Bickford PC, Freedman R (1992). Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Research 587, 130-136.
17. Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX (2000). Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behavioural Brain Research 113, 199-206.
18. Norén U, Bjorner A, Sonesson O, Eriksson L (2006). Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement? Schizophrenia Research 85, 302-304.
19. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, et al. (2006). Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Archives of General Psychiatry 63, 630-638.
20. Risch SC, Horner MD, McGurk SR, Palecko S, Markowitz JS, Nahas Z, Devane CL (2007). Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. Schizophrenia Research 93, 131-135.
21. Schilström B, Ivanov VB, Wiker C, Svensson TH (2007). Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 32, 43-53.
22. Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A (1996). Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Molecular Pharmacology 49, 1-6.
23. Schubert MH, Young KA, Hicks PB (2006). Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biological Psychiatry 60, 530-533.
24. Shannon HE, Hart JC, Bymaster FP, Calligaro DO, DeLapp NW, Mitch CH, Ward JS, Fink-Jensen A, Sauerberg P, Jeppesen L, et al. (1999). Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. Journal of Pharmacology and Experimental Therapeutics 290, 901-907.
25. Thomsen T, Kewitz H (1990). Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sciences 46, 1553-1558.